Cargando…
Metabolomics profile in gastrointestinal cancers: Update and future perspectives
Despite recent progress in diagnosis and therapy, gastrointestinal (GI) cancers remain one of the most important causes of death with a poor prognosis due to late diagnosis. Serum tumor markers and detection of occult blood in the stool are the current tests used in the clinic of GI cancers; however...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265149/ https://www.ncbi.nlm.nih.gov/pubmed/32523308 http://dx.doi.org/10.3748/wjg.v26.i20.2514 |
_version_ | 1783541075086934016 |
---|---|
author | Nannini, Giulia Meoni, Gaia Amedei, Amedeo Tenori, Leonardo |
author_facet | Nannini, Giulia Meoni, Gaia Amedei, Amedeo Tenori, Leonardo |
author_sort | Nannini, Giulia |
collection | PubMed |
description | Despite recent progress in diagnosis and therapy, gastrointestinal (GI) cancers remain one of the most important causes of death with a poor prognosis due to late diagnosis. Serum tumor markers and detection of occult blood in the stool are the current tests used in the clinic of GI cancers; however, these tests are not useful as diagnostic screening since they have low specificity and low sensitivity. Considering that one of the hallmarks of cancer is dysregulated metabolism and metabolomics is an optimal approach to illustrate the metabolic mechanisms that belong to living systems, is now clear that this -omics could open a new way to study cancer. In the last years, nuclear magnetic resonance (NMR) metabolomics has demonstrated to be an optimal approach for diseases' diagnosis nevertheless a few studies focus on the NMR capability to find new biomarkers for early diagnosis of GI cancers. For these reasons in this review, we will give an update on the status of NMR metabolomic studies for the diagnosis and development of GI cancers using biological fluids. |
format | Online Article Text |
id | pubmed-7265149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-72651492020-06-09 Metabolomics profile in gastrointestinal cancers: Update and future perspectives Nannini, Giulia Meoni, Gaia Amedei, Amedeo Tenori, Leonardo World J Gastroenterol Review Despite recent progress in diagnosis and therapy, gastrointestinal (GI) cancers remain one of the most important causes of death with a poor prognosis due to late diagnosis. Serum tumor markers and detection of occult blood in the stool are the current tests used in the clinic of GI cancers; however, these tests are not useful as diagnostic screening since they have low specificity and low sensitivity. Considering that one of the hallmarks of cancer is dysregulated metabolism and metabolomics is an optimal approach to illustrate the metabolic mechanisms that belong to living systems, is now clear that this -omics could open a new way to study cancer. In the last years, nuclear magnetic resonance (NMR) metabolomics has demonstrated to be an optimal approach for diseases' diagnosis nevertheless a few studies focus on the NMR capability to find new biomarkers for early diagnosis of GI cancers. For these reasons in this review, we will give an update on the status of NMR metabolomic studies for the diagnosis and development of GI cancers using biological fluids. Baishideng Publishing Group Inc 2020-05-28 2020-05-28 /pmc/articles/PMC7265149/ /pubmed/32523308 http://dx.doi.org/10.3748/wjg.v26.i20.2514 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Review Nannini, Giulia Meoni, Gaia Amedei, Amedeo Tenori, Leonardo Metabolomics profile in gastrointestinal cancers: Update and future perspectives |
title | Metabolomics profile in gastrointestinal cancers: Update and future perspectives |
title_full | Metabolomics profile in gastrointestinal cancers: Update and future perspectives |
title_fullStr | Metabolomics profile in gastrointestinal cancers: Update and future perspectives |
title_full_unstemmed | Metabolomics profile in gastrointestinal cancers: Update and future perspectives |
title_short | Metabolomics profile in gastrointestinal cancers: Update and future perspectives |
title_sort | metabolomics profile in gastrointestinal cancers: update and future perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265149/ https://www.ncbi.nlm.nih.gov/pubmed/32523308 http://dx.doi.org/10.3748/wjg.v26.i20.2514 |
work_keys_str_mv | AT nanninigiulia metabolomicsprofileingastrointestinalcancersupdateandfutureperspectives AT meonigaia metabolomicsprofileingastrointestinalcancersupdateandfutureperspectives AT amedeiamedeo metabolomicsprofileingastrointestinalcancersupdateandfutureperspectives AT tenorileonardo metabolomicsprofileingastrointestinalcancersupdateandfutureperspectives |